FindTrial
Sign In

Tests are being carried out to verify whether the Psotran Fluid product is effective and safe for people with Psoriasis, Dermatitis and Ichthyosis

Single-blind study of efficacy and safety of the product Psotran Fluid in humans suffering from Psoriasis, Dermatitis and Ichthyosis

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
REBEC
Registry ID
RBR-4x5dhpc
Enrollment
Unknown
Registered
2025-07-24
Start date
2025-03-31
Completion date
Unknown
Last updated
2025-10-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Wound Healing

Interventions

Proof of the efficacy and safety of Psotran Fluid formulated to treat humans suffering from psoriasis, ichthyosis and dermatitis. The study is conducted in a single group, in a single-blind, in vivo c
E04.987

Sponsors

Nipo Serviços Médicos SS Ltda
Lead Sponsor
Instituto de Saúde e Bem Estar da Mulher
Collaborator

Eligibility

Age
18 Years to 90 Years

Inclusion criteria

Inclusion criteria: Patient of both sexes. Over 18 years old with a maximum age of 90 years. With lesions compatible with Psoriasis, Eczema and Ichthyosis, in the initial phase of treatment

Exclusion criteria

Exclusion criteria: Pregnancy. Neonates. Sensitivity to drug components

Design outcomes

Primary

MeasureTime frame
To prove the efficacy and safety of Psotran Fluid in humans in the treatment of excessive dry skin affected by Psoriasis, Dermatitis and Ichthyosis—

Secondary

MeasureTime frame
No secondary outcomes are expected—

Countries

Brazil

Contacts

Public ContactFrederico Viana

TCI Laboratório Biotecnológico Ltda

frederico@tcilab.com.br+55 38 99886-3565

Outcome results

None listed

Source: REBEC (via WHO ICTRP)